Primary biliary cirrhosis

Lancet

Volumn 350, Issue 9081, 1997, Pages 875-879

  Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRION ANTIBODY; PYRUVATE DEHYDROGENASE COMPLEX;

HUMAN; LIVER TRANSPLANTATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW;

EID: 0030826869     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)05419-6     Document Type: Review

References (50)

1. Metcalf J, Howel D, James O, Bhopal R. Primary biliary cirrhosis: epidemiology helping the clinician. BMJ 1996; 312: 1181-82.
2. Myszor M, James O. The epidemiology of primary biliary cirrhosis in northern England: an increasingly common disease? QJM 1990; 75: 377-85.
3. Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol 1994; 20: 698-701.
4. Manns M, Kruger M. Immunogenetics of chronic liver diseases. Gastroenterology 1994; 106: 1676-79.
5. Christensen E, Crowe J, Doniach D, Tygstrup N, Williams R. Clinical pattern and course of disease in primary biliary cirrhosis based on analysis of 236 patients. Gastroenterology 1980; 78: 236-46.
6. Metcalf J, Mitchison H, Palmer J, Jones D, Bassendine M, James O. Natural history of primary biliary cirrhosis. Lancet 1996; 348: 1399-1402.
7. Mahl T, Shockcor W, Boyer J. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years J Hepatol 1994; 20: 707-13.
8. Culp K, Fleming C, Duffy J, Baldus W, Dickson E. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982; 57: 365-70.
9. Sorensen HT, Thulstrup A, Friis S, et al. Cancer risk in patients with liver cirrhosis: a registry study based on 850 000 person years. J Hepatol 1997; 26 (suppl 1): 101.
10. Romics L, Nemesanszky E, Szalay A, Tresch J, Karadi I. Lipoprotein (A) concentration and phenotypes in primary biliary cirrhosis. Clin Chem Acta 1996; 255: 165-71.
11. Potter BJ, Elias E, Thomas HC, Sherlock S. Complement metabolism in chronic liver disease. Gastroenterology 1980; 78: 1034-40.
12. Bandin O, Courvalin J, Poupon R, Dubel L, Homberg J, Johanet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996; 23: 1020-24.
13. Nickowitz RE, Wozniak R, Schaffner F. Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis. Gastroenterology 1994; 106: 193-99.
14. Jones D. T-cell autoimmunity in primary biliary cirrhosis. Clin Sci 1996; 91: 551-58.
15. Leung PSC, Van de Water J, Coppel R, Nakanuma Y, Monoz S, Gershwin E. Molecular aspects and pathological basis of primary biliary cirrhosis. J Autoimmun 1996; 9: 119-28.
16. Czaja A. The variant forms of autoimmune hepatitis. Ann Intern Med 1996; 125: 588-98.
17. Tsuneyama K, Van de Water J, Van Thiel D, et al. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis. Hepatology 1995; 22: 1440-46.
18. Invernizzi P, Crosignani A, Battezzati P, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25: 1090-95.
19. Heathcote EJ. Autoimmune cholangitis. Gut 1997; 30: 440-42.
20. Maddrey WC. Sarcoidosis and primary biliary cirrhosis. N Engl J Med 1983; 308: 588-90.
21. Ludwig J. New Concepts in biliary cirrhosis. Semin Liver Dis 1987; 7: 293-301
22. Garrido M, Hubscher S. Accuracy of staging in primary biliary cirrhosis J Pathol 1996; 49: 556-59
23. Shapiro J, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979; 20: 137-140.
24. Dickson E, Grambsch P, Fleming T. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10: 1-7
25. Christensen E, Altman D, Neuberger J, de Stavola B, Tygstrup N, Williams R. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. Gastroenterology 1993; 105: 1865-76.
26. Gershwin M, Mackay I. Primary biliary cirrhosis: paradigm, or paradox for autoimmunity? Gastroenterology 1991; 100: 822-22
27. Spengler U, Leifeld L, Braunschweiger I, Dumoulin F, Lechmann M, Sauerbruch T. Anomalous expression of co-stimulatory molecules B7-1, B7-2 and CD28 in primary biliary cirrhosis. J Hepatol 1997; 26: 31-36.
28. Joplin R, Lindsay JG, Hubscher S, et al. Distribution of dihydrolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis. Hepatology 1991; 14: 442-47.
29. Krams S, Surth C, Coppel R, Ansari A, Ruebner B, Gershwin M. Immunisation of experimental animals with dihydrolipoamide acetyl transferase as a recombinant polypeptide generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology 1989; 9: 411-16.
30. Kaplan M. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-80.
31. Xu L, Guo L, Joplin R, et al. Viral induction of primary biliary cirrhosis. J Hepatol 1997; 26 (suppl 1): 61.
32. Medina J, Martinez-Anso E, Vazquez J, Prieto J. Decreased anion exchanger-2 immunoreactivity in the liver of patients with primary cirrhosis. Hepatology 1997; 25: 12-17.
33. Jones EA, Bergasa N. Why do cholestatic patients itch? Gut 1996; 38: 644-45
34. Swain M, Maric M. Defective corticotropin-releasing hormone mediated neuroendocrine and behavioural responses in cholestatic rats: implications for cholestatic disease-related sickness behaviors. Hepatology 1995; 22: 1560-64
35. Rosen H. Bones and primary biliary cirrhosis. Hepatology 1995; 21: 253-55.
36. Carithers R, Luketic V, Peters M, et al. Extended follow-up of patients in the US multi-center trial of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1996; 110: A1163.
37. Heathcote EJ, Lindor K, Poupon R, et al. Combined analysis of French, American and Canadian randomized trial of ursodeoxycholic acid therapy in primary biliary cirrhosis. Gastroenterology 1996; 110: A1082
38. Kilmurry M, Heathcote EJ, Cauchdudek K, et al. Is the Mayo model useful for predicting survival after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996; 23: 1148-50.
39. Batts K, Jorgensen R, Dickson E, Lindor K. Effect of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. Am J Gastroenterol 1996; 91: 2314-17.
40. Pares A, for the Spanish Association for the study of the liver. Long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid: results of a randomised, double-blind, placebo-controlled trial. J Hepatol 1997; 26 (suppl 1): 166.
41. van Hoogstraten H, van Buuren H, ten Kate F, Hansen B, van Berne Henegouwen G, Schalm S. Five year sustained biochemical improvement in ursodeoxycholic acid (UDCA) treated primary biliary cirrhosis (PBC) does not preclude disease progression. J Hepatol 1997; 26 (suppl 1): 169.
42. Beuers U, Kullak-Ublick G, Paumgartner G. Mechanism of action of UDCA in cholestatic syndromes. In: Alvaro D, Benedetti A, Strazzabosco M, eds. Vanishing bile duct syndrome - pathophysiology and treatment. Dordrecht: Kluwer Academic Publishers, 1997: 230-39.
43. Pasha T, Heathcote J, Cauchdudek K, et al. Cost-effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1996; 24: 169.
44. Pasha TM, Jorgensen R, Dickson ER, Therneau T, Lindor K. Early predictors of treatment failure in patients treated with ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterology 1996; 110: A1290
45. Neuberger J. Immune effects of ursodeoxycholic acid. In: Berg P, Lohse A, Tiegs C, Wendel O, eds. Autoimmune liver disease. Lancaster: Kluwer Academic Publishers (in press).
46. Wiesner R, Porayako M, Dickson E, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992; 16: 1290-99.
47. Ricci P, Therneau T, Malinchoc M, et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic disease. Hepatology 1997; 25: 672-77.
48. Neuberger J. Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis. Liver Transplant Surg 1995; 1: 109-15.
49. Navasa M, Forns X, Sanchez V, et al. Quality of life, major medical complications and hospital service utilisation in patients with primary biliary cirrhosis after liver transplantation. J Hepatol 1996; 25: 129-34.
50. Van der Water J, Gerson L, Ferrell L, et al. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 1996; 24: 1079-84.